SCHEMBL6727005

SCHEMBL6727005

COc1ccccc1NC(=O)N(S)C(C(=O)Nc1cccc(C)c1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.50
KMT2A Q03164 9/20 0.50
MEN1 O00255 8/20 0.50
CASP3 P42574 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 4/20 0.46
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
THRB P10828 1/20 0.42
HTT P42858 1/20 0.42
GFER P55789 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715747 0.90 MAPT (0.52) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6719403 0.85 ALDH1A1 (0.46) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6719260 0.85 MAPT (0.51) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6715735 0.84 TRPV1 (0.48) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6719880 0.84 MAPT (0.58) MAPTKMT2AMEN1CASP3SENP7
SCHEMBL6717589 0.82 MEN1 (0.48) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6723214 0.82 ALDH1A1 (0.52) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6715691 0.81 MAPT (0.54) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6726997 0.80 MAPT (0.50) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL6722745 0.80 MAPT (0.53) MAPTKMT2AMEN1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MAPT 694/4885KMT2A 1656/4885MEN1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.